Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases (Q42721685)

5 November 2017

title

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases (English)

1 reference

5 November 2017

3

1 reference

5 November 2017

6

1 reference

5 November 2017

5

M Debiec-Rychter

1 reference

5 November 2017

E Lierman

1

1 reference

5 November 2017

S Smits

series ordinal

2

1 reference

5 November 2017

B Dewaele

series ordinal

4

1 reference

5 November 2017

language of work or name

1 reference

17 January 2012

1 reference

5 November 2017

1 reference

5 November 2017

volume

26

1 reference

5 November 2017

issue

7

1 reference

5 November 2017

page(s)

1693-1695

1 reference

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.8

1 reference

Dimensions Publication ID

5 November 2017

1045977157

0 references

1 reference